Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

February 22, 2006 at 10:28 AM

Biotech sales up 17 percent

Biotech drug sales are growing at a faster pace than prescription drugs as a whole and now represent 13 percent of U.S. sales, according to an IMS Health report released today.

Complex therapies such as Enbrel and Rituxan from biotech giants Amgen and Genentech, respectively, helped grow biotech sales to $32.8 billion in 2005, up 17 percent from 2004.

2005 prescription drug sales increased 5.4 percent to $251.8 billion.

Major pharmaceutical companies such as Wyeth expect more of their future sales to come from biotech drugs. The company’s research and development head told Reuters that this category could reach 40 percent of sales within a decade, up from 25 percent currently.

Seattle’s Trubion Pharmaceuticals, like many young biotech companies, has benefited from this trend. It announced a deal last month with Wyeth centering on a technology platform that could improve biotech drug development. The deal could be worth $800 million or more if certain goals are met.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►